Summary
The disposition of cisplatin was evaluated in 28 children and adolescents with cancer, as part of a phase II clinical trial. Patients received either 30 mg/m2 (11) or 90 mg/m2 (17) of cisplatin as a 6-h IV infusion. Serum samples and divided urine collections were obtained over 48 h following completion of the cisplatin infusion, and were assayed in duplicate for total platinum by atomic absorption spectrophotometry. Serum samples obtained up to 4 h after three cisplatin infusions were assayed for parent (free) cisplatin following ultrafiltration. The mean (±SE) elimination half-life of free cisplatin in serum was 1.3 (±0.4) h. Serial serum concentrations of total platinum following 90 mg/m2 dosages were adequately described by a biexponential equation. The mean (±SE) serum T1/2α of total platinum was 0.42 (±0.10) h and the mean (±SE) T1/2β was 44.43 (±8.24) h. The intercompartment distribution rate constants of a two-compartment kinetic model indicate extensive tissue accumulation of total platinum, with a rate of transport into tissue compartments (K12) that is about six times the rate of transport out of tissues (K21). The mean (±SE) renal clearance of total platinum from 0–3 h was 37.36 (±11.96) ml/min/m2 and 35.8 (±13.6) ml/min/m2 for the 30 mg/m2 and 90 mg/m2 groups, respectively. This value decreased to 3.25 (±0.94) and 2.16 (±0.4) ml/min/m2 for the two groups by the 6–12 h interval, and remained between 1 and 3 ml/min/m2 for the duration of the observation period. The ratio of total plantinum clearance to creatinine clearance decreased significantly(P<0.05) beginning 3 h post-infusion. The change in renal clearance of total platinum is apparently a function of two independent first-order processes for renal clearance of parent drug and cisplatin metabolites.
Similar content being viewed by others
References
Bannister SJ, Sternson LA, Repta AJ, et al. (1977) Measurement of free-circulating cis-dichlorodiammineplatinum (II) in plasma. Clin Chem 23:2258–2262
Bristol Laboratories (1978) PlatinolTM, cisplatin for injection: package labeling. Bristol Laboratories, Syracuse NY
Cvitovic E, Spaulding J, Bethune V, et al. (1977) Improvement of cis-dichlorodiammineplatinum (NCC 119875): therapeutic index in an animal model. Cancer 39:1357–1361
DeConti RC, Toftness BR, Lange RC, et al. (1973) Clinical and pharmacological studies with cis-dismminedichloroplatinum (II). Cancer Res 33:1310–1315
Duncan DB (1955) Multiple range and multiple F test. Biometrics 11:1–42
Duncan DB (1957) Multiple range test for correlated heterochesdastic means. Biometrics 13:164–176
Evans WE, Crom WR, Green AA, et al. (1980) cis-Diamminedichloride platinum disposition in children: parameters of a multicompartment kinetic model. In: Nelson VD, Grassi C (eds) Current chemotherapy and infectious disease. American Society for Microbioloy, Washington, pp 1508–1510
Frick GA, Ballentine R, Driever CW, et al. (1979) Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum (II) administered with hydration and mannitol diuresis. Cancer Treat Rep 63:13–16
Gormley PE, Bull JM, LeRoy AF, et al. (1979) Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther 25:351–357
Green AA, Hayes FA, Pratt CB, et al. (1980) Phase II evaluation of cisplatin in children with neuroblastoma and other malignant solid tumors. In: Prestayko AW, Crooke ST, Carter SK (eds) Current status and new developments with cisplatin. Academic Press, New York, London, pp 477–484
Higby DJ, Buchholtz L, Chary K et al. (1977) Kinetics of cis-platinum (DDP) with intensive diuresis. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 18:110
Hill JM, Loeb E, MacLellan A, et al. (1975) Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chmother Rep 59:647–659
Lange RC, Spencer RP, Harder HC (1973) The antitumor agent cis-Pt (NH3)2Cl2: Distribution studies and dose calculations for 193mPt and 195mPt. J Nucl Med 14:191–195
LeRoy AF, Lutz RV, Dedrick RL, et al. (1979) Pharmacokinetic study of cis-dichlorodiammineplatinum (II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic milieu. Cancer Treat Rep 63:59–71
Litterst CL, Gram TE, Dedrick RL, et al. (1976) Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum (II) (NSC 119875) to dogs. Cancer Res 36:2340–2344
Loo JK, Riegelman S (1970) Assessment of pharmacokinetic constants from postinfusion blood curves obtained after IV infusion. J Pharm Sci 59:53–55
Metzler CM (1969) NONLIN: A computer program for estimation in nonlinear situations. Upjohn Comp, Kalamazoo, Michigan (Technical Report no. 7297/69/7297/005)
Piel JJ, Rayadu GVS, Perlia CP, et al. (1974) Use of neutron activation analysis to study excretion of cis-diamminedichloroplatinum (DDP) in cancer patients. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 15:111
Pratt CB, Hayes FA, Green AA, et al. (to be published) Phase II-pharmacokinetic evaluation of cis-diamminedichloroplatinum (II) in children with malignant solid tumors. Cancer Treat Rep
Smith PHS, Taylor DM (1974) Distribution and retention of the antitumor agent 195mPt-cis-dichlorodiammineplatinum (II) in man. J Nucl Med 15:349–351
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Crom, W.R., Evans, W.E., Pratt, C.B. et al. Cisplatin disposition in children and adolescents with cancer. Cancer Chemother. Pharmacol. 6, 95–99 (1981). https://doi.org/10.1007/BF00253017
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00253017